Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00475306 · ClinicalTrials.gov registry record · Phase 4

The Montefiore Metoclopramide Study

A Phase 4 study of Nausea and Extrapyramidal Symptoms, sponsored by Montefiore Medical Center.

Completed
Registry status
Phase 4
Development phase
289
Enrollment target
1
Study location

NCT00475306 is a Phase 4 study of Nausea and Extrapyramidal Symptoms that has completed, run by Montefiore Medical Center. The registered enrollment target is 289 participants, above the 227-participant average among 17 other Nausea trials with a reported enrollment target (27% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00475306, a Phase 4 study of Nausea and Extrapyramidal Symptoms, has completed, sponsored by Montefiore Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
289 participants
Enrollment target
1
Study location

Study Summary

Metoclopramide is a dopamine antagonist frequently used for the treatment of nausea, vomiting, and migraine headaches in Emergency Departments. However, little research has focused on the optimal dose of metoclopramide for treatment of nausea in the emergency department. We propose a randomized, double-blind, placebo controlled trial to investigate the optimal dose of metoclopramide for treatment of nausea.

Interventions

  • DRUG Placebo
  • DRUG metoclopramide 10 mg
  • DRUG Diphenhydramine 25 mg
  • DRUG Metoclopramide 20 mg

Study Locations (1)

New York

  • Montefiore Medical Center - The Bronx

Trial Details

FieldValue
Enrollment Target 289 participants
Start Date 2007-05
Est. Completion 2008-02
Phase Phase 4

Sponsor

Montefiore Medical Center

345 total trials

What the Registry Record Tells You About NCT00475306

The ClinicalTrials.gov registry entry for NCT00475306 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 289 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 227-participant average among 17 other Nausea trials with a reported enrollment target (27% higher). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Nausea appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT00475306 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00475306 about?

NCT00475306 is a clinical study titled "The Montefiore Metoclopramide Study". Metoclopramide is a dopamine antagonist frequently used for the treatment of nausea, vomiting, and migraine headaches in Emergency Departments. However, little research has focused on the optimal dose of metoclopramide for treatment of nausea in the emergency department. We propose a randomized, dou...

What is the current status of trial NCT00475306?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 289 participants. The study started on 2007-05. Estimated completion is 2008-02.

What conditions does trial NCT00475306 study?

This clinical trial studies the following conditions: Nausea, Extrapyramidal Symptoms.

What interventions are being tested in trial NCT00475306?

The interventions under investigation include: Placebo (DRUG), metoclopramide 10 mg (DRUG), Diphenhydramine 25 mg (DRUG), Metoclopramide 20 mg (DRUG).

Who is sponsoring clinical trial NCT00475306?

This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00475306 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nausea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.